NEW YORK CITY -- Postoperative intravitreal methotrexate for retinal detachment led to a significant reduction in reoperation and improved visual acuity, a retrospective chart review showed. The ...

Ducharme is a contributor to TIME. Ducharme is a contributor to TIME. Soon after she started taking the drug methotrexate in February, Jennifer Crow noticed a significant improvement in her ...

Long-term methotrexate treatment in children with juvenile idiopathic arthritis maintains stable lung function without ...

Please provide your email address to receive an email when new articles are posted on . “The disease-modifying anti-rheumatic drug methotrexate is the standard-of-care treatment of inflammatory ...

A subset of patients with CSA who show increased levels of subclinical inflammation at diagnosis may specifically benefit ...

Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

Patients who take methotrexate for a variety of immune-mediated inflammatory diseases and pause taking the drug following receipt of a COVID-19 vaccine dose did not have a higher risk of disease flare ...

Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Split-dose methotrexate had greater efficacy and reduced the need for additional disease-modifying ...

In July 2022, the US Food and Drug Administration (FDA) expanded the labeling of Krystexxa (pegloticase; Horizon Therapeutics), a PEGylated uric acid-specific enzyme, to include coadministration with ...